Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an…
Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade Cytokine Release Syndrome observed…